Advances in genomics and information technology are ushering in a new era for oncology drug development, but biopharmaceutical companies must move the conversation from cost to value.

Immuno-oncology studies are getting increasingly complex, but sponsors can minimize risks by working more collaboratively with CROs and trial sites.

Quintiles Blog

Fresh ideas and insights from our experts around the globe


Quintiles Authors

Vice President and Head, Oncology Center of Excellence

Senior Director, Head of Oncology Center of Excellence

Peer-Reviewed Publications
Cancer drug development in China: recent advances and future challenges.
Drug Discov Today. 2015 Jun;20(6):766-771.
Read more
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer.
Ann Oncol. 2015 Jan;26(1):179-85.
Read more
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
Neuro Oncol. 2015 May 26. pii: nov083. [Epub ahead of print]
Read more
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.
J Antimicrob Chemother. 2015 Jul 1. pii: dkv170. [Epub ahead of print]
Read more
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.
Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14.
Read more